Merck built a wall of patents that keeps a cancer drug's price – and its profits – high. Hospitals often add to the cost for ...

Merck & Co.'s Keytruda in the U.S. starts at $12,000 for a 200 mg dose. Costs go up from there based on the insurer, provider ...

How Merck keeps the price of its lifesaving cancer drug, Keytruda, sky-high, locking out patients and squeezing health care ...

What is Keytruda and how does it work? Experts explain the cancer immunotherapy as a global investigation raises concerns ...

Keytruda's first approval by US FDA came in the year 2014 for advanced skin cancer. Now, the immunotherapy drug is being used ...

What is the Cancer Calculus investigation? The Cancer Calculus is a yearlong investigation by the International Consortium of ...

A game changer in cancer treatment, Keytruda, works by harnessing the body’s immune system to attack cancer cells. While its ...

First approved by the US FDA in 2014 for advanced skin cancer, Keytruda is now used globally for certain lung cancers, ...

A cross-border investigation by DW and ICIJ reveals how pricing and patents helped turn a life-saving medicine into one of ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in ...

First pivotal Phase 3 trial to show superiority of KEYTRUDA plus a TROP2 antibody-drug conjugate, Trodelvy, versus standard of care in first-line metastatic TNBC “These results have the potential to ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...